XRCC3 and neoplasm: In 3 PDX models from the responder group without BRCA1/2 mutations or BRCA1 promoter methylation, we identified mutations in the DDR genes XRCC3 (HBCx-14), TONSL (HBCx-33) and ORC1 (T302), that were present also in the matched patients’ primary tumours.